HanchorBio Inc. (7827)

Overview

HanchorBio Inc. is a cutting-edge biotechnology company founded in 2020 and based in Taipei, Taiwan. With a specialized focus on immuno-oncology, HanchorBio is committed to creating next-generation biologic therapies with the goal of enhancing the immune system's capabilities to fight cancer. The cornerstone of the company's innovation is the proprietary Fc-Based Designer Biologics (FBDB™) technology platform, which is designed to engineer multifunctional molecules. These molecules are unique in their ability to simultaneously activate both innate and adaptive immune responses, effectively targeting and destroying tumors.

The company's therapeutic pipeline showcases advanced candidates, including HCB101, a fusion protein targeting CD47, which is currently in Phase 2 clinical trials in key markets such as Taiwan, the United States, and China. HanchorBio operates on a global scale, expanding its footprint in the United States and mainland China while anchored in its headquarters in Taiwan. The executive team is comprised of experts with extensive experience in biologics research and regulatory processes. Through established strategic partnerships and significant investments from reputable institutional investors, HanchorBio is poised to emerge as a major innovator in the biotechnology and pharmaceutical landscapes, aimed at addressing critical unmet medical needs in oncology and advancing the field of precision immunotherapy.

Products and Services

• HCB101

  HCB101 is a pioneering CD47-targeting fusion protein designed to enhance the immune system's ability to identify and eliminate cancer cells. Currently undergoing Phase 2 clinical trials, HCB101 aims to demonstrate improved therapeutic efficacy and safety in cancer treatment across various patient populations in Taiwan, the United States, and China.

• Fc-Based Designer Biologics (FBDB™) Technology Platform

  This proprietary technology platform enables the engineering of multifunctional biologics that can orchestrate a simultaneous activation of innate and adaptive immune responses. This innovative approach is aimed at providing more effective immunotherapy options for cancer patients, potentially leading to better treatment outcomes.

• Immuno-oncology Therapeutics Pipeline

  HanchorBio’s pipeline features a range of advanced therapeutic candidates aimed at harnessing the immune system in the fight against various types of cancers. The focus is on innovative biologic therapies that can offer new hope and treatment avenues for patients facing serious oncological challenges.

• Global Collaboration and Partnerships

  HanchorBio actively seeks strategic partnerships across the biotechnology and pharmaceutical sectors to leverage complementary expertise and resources. Through collaboration with leading research institutions and companies, HanchorBio aims to enhance its research capabilities and broaden the impact of its immuno-oncology innovations.